

3 December 2010

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000



**cyclo**medica  
**molecula**r imaging  
**techn**egas

Cyclopharm Limited  
ABN 74 116 931 250  
Suite 630 Level 6  
1 Queens Road  
Melbourne Victoria 3004  
Australia  
T 61 3 9867 2811  
F 61 3 9820 5957  
[www.cyclopharm.com](http://www.cyclopharm.com)

### **Cyclopet Receives TGA License**

Cyclopharm Limited's (ASX: CYC) wholly owned subsidiary Cyclopet Pty Limited (Cyclopet) is pleased to announce that the cyclotron production and research facility located at Macquarie University Hospital (MUH) has received Good Manufacturing Process (GMP) license approval from the Australian Therapeutic Goods Administration (TGA).

Cyclopet's facility at MUH is Australia's most technologically advanced production and research facility for the manufacture of PET radiopharmaceuticals. The facility is also Australia's first commercial cyclotron radiopharmaceutical production centre to be collocated within a hospital.

Cyclopet will commence its commercial activities by producing the radiopharmaceutical compound F<sup>18</sup> Flurodeoxyglucose (FDG). FDG is the most commonly used injectible radioactive marker utilised in Positron Emission Tomography (PET). Also known as molecular imaging, PET is the fastest growing nuclear medicine diagnostic imaging modality in the world.

115,000 Australians will be diagnosed with cancer this year. This figure represents a 10% increase since 2006. Cyclopet's products and research will play a major role in early diagnosis and therapeutic management of these cancer patients. PET is clinically proven to better identify the location and extent of certain active cancer cells in the body as well as many neurodegenerative diseases.

Cyclopet will provide radiopharmaceuticals for both private and public PET departments including Macquarie Medical Imaging (MMI). MMI, Cyclopharm's medical imaging joint venture with Alfred Health Solutions, has been operational since July 2010. MMI's facility at MUH provides patient's at the 183 bed hospital and neighbouring suburbs access to state of the art imaging facilities including PET scanning. MMI together with Cyclopet represents a fully aligned diagnostic, therapeutic and research platform.

Along with filling an immediate demand for commercial PET radiopharmaceuticals, Cyclopharm will be engaged in education as well as research and development projects with scientists and clinicians affiliated with the Australian Graduate School of Advanced Medicine, our joint venture partners and industry partners both within Australia and globally.

The Director's consider this achievement a key step in increasing shareholder value.

James McBrayer  
**Managing Director**

#### **Contact details:**

Mr James McBrayer  
Managing Director  
Cyclopharm Limited  
T: +61 2 9541 0411

## **Background**

### **Cyclopharm Limited**

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community. The Company's mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

### **Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

### **Positron Emission Tomography (PET)**

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

### **Macquarie University Hospital and the Macquarie University School of Advanced Medicine**

Macquarie University Hospital is a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Hospital is a state of the art facility that delivers health education and research on site.

### **Macquarie Medical Imaging**

Cyclopharm formed a joint venture with Alfred Health Solutions to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging ("MMI") represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.

The combination of state of the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.